Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| ID-RCB | Registry Identifier | 2024-A00552-45 |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Feasibility and efficiency of Screening for Neurodevelopmental Disorders by an Advanced Practice Nurse in Children aged 1 to 5 with Congenital Heart Disease
Congenital heart disease (CHD) is the leading cause of birth defects. Over 90% of children born with CHD reach adulthood. 50% of them will develop a neurodevelopmental disorder (NDD) that could affect life and long-term prognosis, including scholar and social integration and health related quality of life.
In France, there is a lack of medical resources to screen NDD in this population and to refer patients for appropriate and early treatment.
Investigators plan to propose a systematic early screening of NDD by an Advanced Practice Nurse (APN) during the usual cardiac follow-up. Children with CHD aged 1 to 5 will be included. If NDD is suspected, the patient will be referred to a neuropsychologist for NDD diagnosis confirmation and management planning. Patients with higher NDD risks (neonatal cardiac surgery) will benefit from a systematic neuropsychologist evaluation.
This study will investigate the feasibility and performance of an APN screening in this NDD-high risk population.
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Screening for neurodevelopmental disorders by an advanced practice nurse | Experimental |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Screening for neurodevelopmental disorders by an advanced practice nurse | Other | Screening for neurodevelopmental disorders by an advanced practice nurse with Ages & Stages Questionnaires (ASQ-3) and Haute Autorité de Santé (HAS) identification scale |
| Measure | Description | Time Frame |
|---|---|---|
| Sensibility of the IPA screening for neurodevelopmental disorder (NDD) on the whole population studied | This will be evaluated by comparing the results of the IPA screening (using both HAS scale and ASQ-3 parent's questionnaire) with results of the advanced neuropsychologist assessment. A positive IPA screening is defined by a NDD alert using the HAS scale and/or the ASQ-3 parent's questionnaire. The advanced neuropsychologist assessment will be done only for patients with CHD with a positive IPA screening. | 4 months (to obtain the neurophysiologist assessment) |
| Measure | Description | Time Frame |
|---|---|---|
| Feasibility of the IPA screening for NDD | This rate will be calculated by dividing the complete IPA screenings (including HAS and the ASQ-3 parent's questionnaire) and children coming to the Complex Congenital Heart Defects consultation during the study period. | 18 months |
| Performance (sensibility) of the IPA screening for NDD on the NDD high risk population |
Not provided
Inclusion Criteria:
Exclusion Criteria:
Not provided
Not provided
Not provided
Not provided
| Name | Role | Phone | Extension | |
|---|---|---|---|---|
| Marie VINCENTI, MD | Contact | 04 67 33 66 39 | m-vincenti@chu-montpellier.fr | |
| Clinical Research Associate | Contact | 06 67 33 66 32 | recherche-clinique-ccp@chu-montpellier.fr |
Not provided
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| University Hospitial of Montpellier | Recruiting | Montpellier | 34295 | France |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
This will be evaluated by comparing the results of the IPA screening (using both HAS scale and ASQ-3 parent's questionnaire) with results of the advanced neuropsychologist assessment. A positive IPA screening is defined by a NDD alert using the HAS scale and/or the ASQ-3 parent's questionnaire. The advanced neuropsychologist assessment will be done only for patients with CHD with a positive IPA screening. |
| 4 months (to obtain the neurophysiologist assessment) |
| Performance (specificity) of the IPA screening for NDD on the NDD high risk population | This will be evaluated by comparing the results of the IPA screening (using both HAS scale and ASQ-3 parent's questionnaire) with results of the advanced neuropsychologist assessment. A positive IPA screening is defined by a NDD alert using the HAS scale and/or the ASQ-3 parent's questionnaire. The advanced neuropsychologist assessment will be done only for patients with CHD with a positive IPA screening. | 4 months (to obtain the neurophysiologist assessment) |
| Performance (positive predictive value) of the IPA screening for NDD on the NDD high risk population | This will be evaluated by comparing the results of the IPA screening (using both HAS scale and ASQ-3 parent's questionnaire) with results of the advanced neuropsychologist assessment. A positive IPA screening is defined by a NDD alert using the HAS scale and/or the ASQ-3 parent's questionnaire. The advanced neuropsychologist assessment will be done only for patients with CHD with a positive IPA screening. | 4 months (to obtain the neurophysiologist assessment) |
| Performance (negative predictive value) of the IPA screening for NDD on the NDD high risk population | This will be evaluated by comparing the results of the IPA screening (using both HAS scale and ASQ-3 parent's questionnaire) with results of the advanced neuropsychologist assessment. A positive IPA screening is defined by a NDD alert using the HAS scale and/or the ASQ-3 parent's questionnaire. The advanced neuropsychologist assessment will be done only for patients with CHD with a positive IPA screening. | 4 months (to obtain the neurophysiologist assessment) |
| Prevalence of NDD in the high risk population | 18 months |
| Institut Marin Saint-Pierre | Not yet recruiting | Palavas-les-Flots | 34250 | France |
|
| CHU Bordeaux Haut-Lévêque | Not yet recruiting | Pessac | 33600 | France |
|
| ID | Term |
|---|---|
| D065886 | Neurodevelopmental Disorders |
| D006330 | Heart Defects, Congenital |
| ID | Term |
|---|---|
| D001523 | Mental Disorders |
| D018376 | Cardiovascular Abnormalities |
| D002318 | Cardiovascular Diseases |
| D006331 | Heart Diseases |
| D000013 | Congenital Abnormalities |
| D009358 | Congenital, Hereditary, and Neonatal Diseases and Abnormalities |
Not provided
Not provided
| ID | Term |
|---|---|
| D008403 | Mass Screening |
| ID | Term |
|---|---|
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D006306 | Health Surveys |
| D011795 | Surveys and Questionnaires |
| D003625 | Data Collection |
| D004812 | Epidemiologic Methods |
| D008919 | Investigative Techniques |
| D003954 | Diagnostic Services |
| D011314 | Preventive Health Services |
| D006296 | Health Services |
| D005159 | Health Care Facilities Workforce and Services |
| D017531 | Health Care Evaluation Mechanisms |
| D011787 | Quality of Health Care |
| D017530 | Health Care Quality, Access, and Evaluation |
| D011634 | Public Health |
| D004778 | Environment and Public Health |
| D015980 | Public Health Practice |
Not provided
Not provided